These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 32203070)
21. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429 [TBL] [Abstract][Full Text] [Related]
22. Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate. Hung SC; Wang SS; Li JR; Chen MC; Yang CK; Chen CS; Ho HC; Chiu KY; Cheng CL; Chang CH; Ou YC Anticancer Res; 2018 Sep; 38(9):5429-5436. PubMed ID: 30194199 [TBL] [Abstract][Full Text] [Related]
23. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Belic J; Graf R; Bauernhofer T; Cherkas Y; Ulz P; Waldispuehl-Geigl J; Perakis S; Gormley M; Patel J; Li W; Geigl JB; Smirnov D; Heitzer E; Gross M; Speicher MR Int J Cancer; 2018 Sep; 143(5):1236-1248. PubMed ID: 29574703 [TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort. Lim J; Amantakul A; Shariff N; Lojanapiwat B; Alip A; Ong TA; Thevarajah S; Ahmayuddin F; Mathew A; Sriplakich S; Vuthiwong J; Chong FLT; Saad M Cancer Med; 2020 Jul; 9(13):4613-4621. PubMed ID: 32374087 [TBL] [Abstract][Full Text] [Related]
25. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595 [TBL] [Abstract][Full Text] [Related]
26. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Romero-Laorden N; Lozano R; Jayaram A; López-Campos F; Saez MI; Montesa A; Gutierrez-Pecharoman A; Villatoro R; Herrera B; Correa R; Rosero A; Pacheco MI; Garcés T; Cendón Y; Nombela MP; Van de Poll F; Grau G; Rivera L; López PP; Cruz JJ; Lorente D; Attard G; Castro E; Olmos D Br J Cancer; 2018 Oct; 119(9):1052-1059. PubMed ID: 30131546 [TBL] [Abstract][Full Text] [Related]
27. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030 [TBL] [Abstract][Full Text] [Related]
28. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683 [TBL] [Abstract][Full Text] [Related]
29. Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. Stuopelyte K; Sabaliauskaite R; Bakavicius A; Haflidadóttir BS; Visakorpi T; Väänänen RM; Patel C; Danila DC; Lilja H; Lazutka JR; Ulys A; Jankevicius F; Jarmalaite S J Urol; 2020 Jul; 204(1):71-78. PubMed ID: 32068491 [TBL] [Abstract][Full Text] [Related]
30. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075 [TBL] [Abstract][Full Text] [Related]
31. Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. Binder M; Zhang BY; Hillman DW; Kohli R; Kohli T; Lee A; Kohli M Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409606 [TBL] [Abstract][Full Text] [Related]
32. Germline Variant in Hahn AW; Gill DM; Poole A; Nussenzveig RH; Wilson S; Farnham JM; Stephenson RA; Cannon-Albright LA; Maughan BL; Agarwal N Mol Cancer Ther; 2019 Mar; 18(3):726-729. PubMed ID: 30587554 [TBL] [Abstract][Full Text] [Related]
33. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372 [TBL] [Abstract][Full Text] [Related]
34. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. Pilon D; Queener M; Lefebvre P; Ellis LA J Med Econ; 2016 Aug; 19(8):777-84. PubMed ID: 27031255 [TBL] [Abstract][Full Text] [Related]
35. Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors. Fan L; Dong B; Chi C; Wang Y; Gong Y; Sha J; Pan J; Shangguan X; Huang Y; Zhou L; Xue W BMC Urol; 2018 Dec; 18(1):110. PubMed ID: 30509237 [TBL] [Abstract][Full Text] [Related]
36. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596 [No Abstract] [Full Text] [Related]
37. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967 [TBL] [Abstract][Full Text] [Related]
39. Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors. Jimenez Romero ME; Gallego MC; Navarro Serrato JC; Sanchez Hurtado MA; Santotoribio JD Anticancer Res; 2021 Aug; 41(8):3955-3968. PubMed ID: 34281859 [TBL] [Abstract][Full Text] [Related]
40. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Attard G; de Bono JS; Logothetis CJ; Fizazi K; Mukherjee SD; Joshua AM; Schrijvers D; van den Eertwegh AJ; Li W; Molina A; Griffin TW; Kheoh T; Ricci DS; Zelinsky K; Rathkopf DE; Scher HI; Ryan CJ Clin Cancer Res; 2015 Apr; 21(7):1621-7. PubMed ID: 25593303 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]